Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice

Area of Science:

• Immunology
• Cardiovascular Medicine
• Vaccinology

Background:

• Vaccines are increasingly developed for non-infectious diseases like cancer and autoimmune disorders.
• Vaccines targeting self-antigens require careful safety and efficacy evaluation, balancing humoral immunity with T cell non-activation.
• The immunological profile and safety of angiotensin II (Ang II) vaccines remain largely uncharacterized.

Purpose of the Study:

• To evaluate the efficiency and safety of an Ang II peptide vaccine in a mouse model.
• To assess the humoral and T cell immune responses to the Ang II vaccine.
• To determine the vaccine's impact on blood pressure and cardiovascular parameters.

Main Methods:

• Mice were immunized with Ang II conjugated to keyhole limpet hemocyanin (KLH).
• Humoral response was measured by anti-Ang II antibody production and blockade of Ang II signaling.
• T cell activation was assessed via proliferation and lymphokine production.
• Cardiovascular effects were evaluated in an Ang II-infused mouse model.

Main Results:

• Immunization successfully induced anti-Ang II antibodies that blocked Ang II signaling.
• The Ang II vaccine did not activate T cells, while KLH did.
• Vaccinated mice showed significantly reduced systolic blood pressure, cardiac hypertrophy, and fibrosis.
• No inflammatory cell accumulation was observed in vaccinated mice.

Conclusions:

• The Ang II peptide vaccine is effective in reducing blood pressure and preventing cardiovascular complications in mice.
• The vaccine elicits a beneficial humoral response while avoiding detrimental T cell activation.
• These findings suggest that Ang II vaccines are a potential therapeutic strategy for hypertension and related cardiovascular diseases with a favorable safety profile.